New synthetic direct and indirect factor Xa or factor Ila inhibitors are increasingly used for the prevention and treatment of thrombotic disorders, including patients suffering from antiphospholipid syndrome. In this study, the effects of the synthetic direct factor Xa inhibitor DX-9065a, the indirect synthetic heparinomimetic pentasaccharide, and the direct factor IIa inhibitor Argatroban were studied. These two widely used assays for the detection of lupus anticoagulant, namely the tissue thromboplastin inhibition (TTIT) and the dilute Russell viper venom tests (DRVVT) proved useful. The drugs were added to a normal human plasma pool ranging in concentration from 0.04 to 10 Ag/mL. Using the two tests named above, DX-9065a and Argatroban showed a dose-related prolongation of TTIT and DRVVT in the concentration range from 0.04 to 5 Amol/mL, but the pentasaccharide only slightly prolonged the clotting times of Address correspondence and reprint requests to Jawed Fareed,
Serine proteases play an important role in thrombogenesis. In the coagulation cascade, various serine proteases are activated that eventually cause the formation of factors Xa and IIa. Factor Xa is an essential component of the prothrombinase complex and leads to formation of thrombin (1) . The latter is a multifunctional enzyme that plays a part in thrombus formation, platelet activation, cell proliferation, and inflammation. Thus factor Xa and thrombin are important targets for the development of antithrombotic medications. During the past few years, specific inhibitors have been synthesized (2) . Some drugs (synthetic pentasaccharide) that ex-these assays even at high concentrations. Argatroban had the more pronounced effect on both tests when compared with DX-9065a (p<0.001). The most responsive assay for DX-9065a up to a concentration of 2.5 Amol/mL was the DRVVT. For Argatroban both TTIT and DRVVT were equally responsive. Patients whose plasma was tested for suspected lupus anticoagulant and who have been given DX-9065a or Argatroban may have false-positive results with the TTIT tests and DRVVT. This effect should be considered during patient management. These results indicate that these assays could be used for the effective quantitation of the direct factor Xa or factor Ila inhibitors when suitable controls are used. Key Words: Lupus hibit anti-Xa activity require AT III for their inhibitory action, but others (DX-9065a, Argatroban, Melagatran) inhibit factors Xa or IIa directly. The factor Xa and IIa inhibitors exhibit a functional heterogeneity in their action and as a class of new antithrombotic drugs have both functional and structural heterogeneity (1, (3) (4) (5) (6) (7) (8) . This diversity among the factor Xa and thrombin inhibitors influences their laboratory tests designed to measure integrity of the coagulation system in vitro or ex vivo (1, (6) (7) (8) .
The tissue thromboplastin inhibition (TTIT) and the dilute Russell Viper venom tests (DRVVT), based on dilute tissue thromboplastin (dilute prothrombin [PT] ) or snake venom content are designed to detect the lupus anticoagulant (LA) in plasma samples in most modern laboratories (9) (10) (11) . LA is now widely recognized as a definite risk factor for arterial and venous thrombosis. Thus many patients treated with these new serine protease inhibitors will be screened for the detection of this antiphospholipid antibody (12) . The subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and the standartization committee of the International Society on Thrombosis and Haemostasis in 1995 recommended that more than one screening assay be performed to detect or rule out LA (13) . Previously it was shown that the results of the TTIT are influenced by the presence of unfractioned heparin and low-molecularweight heparin (LMWH) in plasma samples and this effect depends on the aXa:aIJa ratio of a given LMWH (14) . In the present in vitro study, we evaluated the effect of direct and indirect synthetic Xa inhibitor Dx9065a and pentasaccharide, as well as the direct synthetic thrombin inhibitor Argatroban on the TTIT and DRVVT.
MATERIALS AND METHODS
The indirect acting synthetic factor Xa inhibitor pentasaccharide (molecular weight 1728 Da) was obtained from Sanofi-Synthelabo (Paris, France). The synthetic peptidomimetic direct anti-Xa agent DX-9065a (molecular weight 571Da) was obtained from Daichii Pharmaceutical (Tokyo, Japan) and direct synthetic thrombin inhibitor Argatroban (molecular weight 526.66Da) was obtained from Mitsubishi-Tokyo Pharmaceuticals/Texas Biotechnology Corporation, (Tokyo, Japan and Houston, USA). Tissue thromboplastin reagent Simplastin® and calcium chloride were from Organon Teknika, (Durham, NC, USA). DRVVT was a commercial kit DVVtest® from American Diagnostica (Greenwich, CT, USA), 0.9% sodium chloride was obtained from Baxter Healthcare Corporation, (Deerfield, IL, USA), and Vacutainer® tubes were from Becton Dickinson (Franklin Lakes, NJ, USA). Normal human plasma (NHP) was a plasma pool prepared from 20 healthy voluntary donors (10 men and 10 women) Blood was drawn by venipuncture following a double syringe technique and placed into Vacutainer® tubes containing 3.2% (0.105 M) trisodium citrate in the ratio of one part of citrate and nine parts of whole blood. The samples were then centrifuged at 2500g for 15 minutes to obtain platelet-poor plasma (PPP) and mixed in equal volumes to prepare NHP.
The pentasaccharide, DX-9065a and Argatroban were reconstituted in saline to obtain a stock concentration of 100 ,ug/mL. The drugs were supplemented individually in NHP and serial dilutions were made to obtain final concentrations of 10.0, 5.0, 2.5, 1.25, 0.62, 0.31, 0.16, 0.08, 0.04, and 0.0 Ag/mL. NHP was used as control.
Micromolar concentrations for the synthetic drugs were determined using their known formula weights. The samples were kept on ice throughout the experiment.
Assay Systems
The TTIT was carried out by a semi-automated method on the Fibrometer (BBL, Microbiology Systems Becton Dickinson and Co, Cockeysville, NY) as per the procedure described by Schleider and associates (9) . Tissue thromboplastin reagent, Simplastin® prepared from rabbit brain and lung tissue was diluted with 0.9% sodium chloride to 1:50 and 1:500 (2% and 0.2%, respectively). The diluted reagent was prewarmed at 37°C for at least 10 minutes before testing. CaCl2 0.025 M was also prewarmed at 37°C.
Procedure of TTI Test
1. 0.1 mL of NHP supplemented with decreasing concentration of each drug was mixed with 0.1 mL 1:50 dilution of Simplastin® and incubated at 37°C for 5 minutes.
2. 0.1 mL of 0.025 M CaCl2 was added and the Fibrometer started simultaneously. 3 . Clotting time was recorded in seconds. 4. Steps 1 through 3 were repeated using 1:500 dilution of Simplastin®.
5. The tests of each dilution of drug were performed in quadruplicate.
Procedure of DRW Test
The DRVV test was performed by a semiautomated procedure on the Fibrometer using a commercial test kit DVVtest®. The reagent was reconstituted according to manufacturers instructions and prewarmed for at least 10 minutes at 37°C.
1. 0.2 mL of NHP supplemented with decreasing concentration of each drug was pipetted into the Fibrometer fibrocup and incubated for 2 minutes at 37°C.
2. 0.2 mL of well-mixed prewarmed reagent was added to the test plasma and simultaneously the Fibrometer timer was started. 3 
Statistical Analysis
Statistical analysis was performed with GraphPad Prism version 2.0 software for Windows (GraphPad Prism Software, San Diego). One-way ANOVA was used to compare the effects of each drug on the TTIT or DRVV tests and a p value less than 0.05 was considered statistically significant.
RESULTS
The results of the TTIT and DVVtesto for various dilutions of DX-9065a, Argatroban and pen-tasaccharide are shown in Tables 1 to 3 both in seconds and as ratio to the control. The two drugs showed dose-dependent prolongation of the TTIT and DVVtest® clotting times in the concentration range of 0.04 to 5 imol/mL, but pentasaccharide had little effect on both clotting tests in vitro ( Figs. 1-3) . The most pronounced prolongation of TTIT in both dilutions was with Argatroban, followed by DX-9065a and pentasaccharide (p<0.001). The same order was also observed with the DVVtest® (p<0.001). Dilution of Simplastin® in TTIT did not change the responsiveness of assay to these drugs since in TTIT 1:50 and TTIT 1:500, similar degrees of (Fig. 1) , in the tissue thromboplastin inhibition test (TTIT) 1:500 dilution (Fig. 2) , and in the dilute Russel viper venom test (DRVVT) (Fig. 3) . Plasma was supplemented with increasing amounts of Dx-9065a, Argatroban, and pentasaccharide reaching final concentrations from 0.0 to 10 pg/mL (means±SEM, n=4). Plasma concentrations were converted to micromolar amounts using the molecular weight of each agent. Tables  1, 2 ). Both the TTIT and DVVtest® tests were more responsive to direct anti-IIa agent Argatroban than to direct anti-Xa agent DX-9065a. The concentration of Argatroban required to double the clotting time from basal in the TTIT and in the DVVtest® was 0.62 ptmol/mL, whereas for DX-9065a it was 2.5 ,umol/mL in the TTIT and 1.25 ,umol/mL in the DVVtest®. For DX-9065a concentrations up to 2.5 A,mol/mL DVVtest® was more responsive than TTIT in both dilutions of Simplastin® (Fig. 4) . DX-9065a at concentrations of 0.16 and 2.5 Atmol/mL prolonged the clotting times of DVVtest® over baseline 1.27 and 2.25fold respectively, but TTIT clotting times at these drug concentrations were prolonged only 1.1 and 2.05-fold. Both TTIT and DWtests showed similar responsiveness to Argatroban and at drug concentrations from 0.08 until 5.0,tmol/mL clotting times of both test systems were prolonged from 1.25 to 4.0-fold relatively to NHP (Fig. 5 ).
DISCUSSION
The in vitro results of supplementation of DX-9065a and Argatroban in NHP show that the TTIT and DVVtest' are prolonged in a concentration-dependent manner over a relatively large concentration range. This is consistent with the literature which points out that newer drugs prolong the clotting times of global coagulation tests in a dose-dependent manner, but to variable degrees. In general, the most sensitive assay for direct thrombin inhibitors is the TT followed by the PT and the APTT tests and for direct Xa inhibitors, the PT followed by the APTT (1,6-7) . DX-9065a prolongs an anti Xa clotting assay Heptest® at high concentrations only (1, 6) . The agent that directly inhibited thrombin showed the greatest increase of the TTIT and DVVtest' clotting time ratios relative to NHP over the entire concentration range, suggesting that the anti-IIa drug Argatroban has more potent effect on the TTIT and DVVtest® than the anti-Xa drug DX-9065a. This is consistent with studies of the effects of four LMWHs having different aXa:aIIa ratios on the TTIT in vitro, which found that LMWH with the lowest aXa:aIIa ratio showed the highest prolongation of TTIT values. The DVVtest® was more sensitive for direct factor Xa inhibitory effect of DX-9065a compared with the TTIT, so clotting assays initiated by factor X activators as Russell viper venom are affected by direct factor Xa inhibitors more strongly than assays initiated by low concentration of tissue factor. The direct thrombin inhibitor Argatroban prolonged clotting times of both these tests equally well. Because there is intrinsic heterogeneity between various thromboplastins and DRVVT reagents, it would be of interest to see whether reagents of differing composition significantly change the relative responsiveness of these assay systems to DX-9065a or Argatroban. According to published data, the heparinomimetic synthetic indirect anti-Xa agent pen-tasaccharide has no effect on global coagulation assays such as PT, APTT, ACT, but the Heptest® an anti-Xa clotting assay is sensitive to this drug (1, 8, 15) . After subcutaneous administration of pentasaccharide (up to 28.6 mg) to healthy human volunteers, no significant changes in PT and APTT were noticed ex vivo (16) . Results of our present in vitro study showed that pentasaccharide only very slightly prolonged the clotting times of TTIT and DVVtestg at therapeutic concentrations. Because this drug very effectively prevents or treat various thrombotic complications in different clinical scenarios, it suggests that the in vitro effect on coagulation tests does not necessarily predict in-vivo effectiveness. CONCLUSION 1. The results of TTIT and DVVtest® are influenced by the presence of direct anti-Xa agent DX-9065a and direct anti-Ila agent Argatroban in the plasma samples. Blood samples from patients who are tested for lupus anticoagulant and are given these drugs may have shown false-positive results. If ex vivo data from patients treated with therapeutic dosages of pentasaccharide are in line with our in vitro results, patients managed with pentasaccharide can be tested for lupus anticoagulant employing TTIT and DVVtest® without drug interference with assay results.
2. The TTIT and DVVtest® values were prolonged in a concentration-dependent fashion over a relatively large concentration range of DX-9065a and Argatroban. The most responsive assay for DX-9065a up to concentration of 2.5 ,tmol/mL was DVVtest®, but for Argatroban both TTIT and DVVtest® were equally responsive. Our results suggest that these assays could be used for the effective quantitation of the direct factor Xa or factor IIa inhibitors when suitable controls are used.
3. Argatroban had more pronounced effect on both tests when compared with DX-9065a, suggesting that agents with direct anti-IIa activity have more potent effect on the TTIT and DVVtest® than the agents with direct anti-Xa activity.
